| Literature DB >> 22848662 |
Xuelin Zhang1, Qun Chen, Chunya He, Weihua Mao, Ling Zhang, Xiaowen Xu, Junfei Zhu, Baofu Chen.
Abstract
Chromosome 8q24 is commonly amplified in many types of cancer, particularly lung cancer. Polymorphisms in this region are associated with risk of different cancers. To investigate the relationship between three single nucleotide polymorphisms (SNPs) (rs1447295, rs16901979 and rs6983267) on 8q24 and lung cancer risk, we conducted an association study in two Han Chinese populations: one population was from Zhejiang Province (576 case patients and 576 control subjects), whereas the other was from Fujian Province (576 case patients and 576 control subjects). We found that rs6983267 was significantly associated with an increased risk of lung cancer in both populations. Compared with the TT genotype, the GG genotype was associated with a significant 1.555-fold increased risk of lung cancer [95% confidence interval (CI) 1.218-1.986, P = 4.0×10(-4)]. This effect was more pronounced in never-smokers [odds ratio (OR) = 2.366, 95% CI 1.605-3.488, P = 1.4×10(-5)]. Analyses stratified by histology revealed that rs6983267 GG genotype was most associated with patients with other histological types (OR = 3.012, 95% CI 1.675-5.417, P = 2.3×10(-4)). The AA genotype of rs1447295 was associated with increased risk for adenocarcinoma compared with the CC genotype (OR = 2.260, 95% CI 1.174-4.353, P = 0.015). Furthermore, the GG genotype of rs6983267 was associated with worse survival in the Zhejiang population (hazard ratio (HR) = 1.646, 95% CI 1.099-2.464, P = 0.016). No association was observed for rs16901979. These results suggest that genetic variations on 8q24 may play significant roles in the development and progression of lung cancer.Entities:
Mesh:
Year: 2012 PMID: 22848662 PMCID: PMC3407045 DOI: 10.1371/journal.pone.0041930
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristic of cases and controls.
| Characterristic | Population 1 | Population 2 | Overall | ||||||
| Cases (%) | Controls (%) |
| Cases (%) | Controls (%) |
| Cases (%) | Controls (%) |
| |
|
| 548 | 556 | 453 | 507 | 1001 | 1063 | |||
|
| |||||||||
| Median (25% quartile B75% quartile) | 58 (51–64) | 58 (52–64) | 0.756 | 58 (52–64) | 59 (53–65) | 0.148 | 58 (52–64) | 58 (52–65) | 0.079 |
|
| |||||||||
| Male | 376 (68.6) | 389 (70.0) | 323 (71.3) | 339 (66.9) | 699 (69.8) | 728 (68.5) | |||
| Female | 172 (31.4) | 167 (30.0) | 0.627 | 130 (28.7) | 168 (33.1) | 0.138 | 302 (30.2) | 335 (31.5) | 0.509 |
|
| |||||||||
| Never | 223 (41.0) | 283 (52.9) | 157 (34.7) | 256 (50.6) | 380 (38.1) | 539 (51.8) | |||
| Current | 231 (42.5) | 203 (37.9) | 178 (39.3) | 164 (32.4) | 409 (41.0) | 367 (35.3) | |||
| Former | 86 (15.8) | 43 (8.0) | 66 (14.6) | 47 (9.3) | 152 (15.2) | 90 (8.6) | |||
| Unknown | 4 (0.7) | 6 (1.1) | <0.001 | 52 (11.5) | 39 (7.7) | <0.001 | 56 (5.6) | 45 (4.3) | <0.001 |
|
| |||||||||
| I | 135 (24.6) | 83 (18.3) | 218 (21.8) | ||||||
| II | 99 (18.1) | 63 (13.9) | 162 (16.2) | ||||||
| III | 172 (31.4) | 190 (41.9) | 362 (36.2) | ||||||
| IV | 111 (20.3) | 113 (24.9) | 224 (22.4) | ||||||
| Missing | 31 (5.7) | 4 (0.9) | 35 (3.5) | ||||||
|
| |||||||||
| Grade 1 +2 | 336 (61.3) | 253 (55.8) | 589 (58.8) | ||||||
| Grade 3 | 167 (30.5) | 195 (43.0) | 362 (36.2) | ||||||
| Missing | 45 (8.2) | 5 (1.1) | 50 (5.0) | ||||||
|
| |||||||||
| Squamous cell carcinoma | 129 (23.5) | 113 (24.9) | 242 (24.2) | ||||||
| Adenocarcinoma | 348 (63.5) | 298 (65.8) | 646 (64.5) | ||||||
| Adenosquamous | 13 (2.4) | 10 (2.2) | 23 (2.3) | ||||||
| Others | 58 (10.6) | 32 (7.1) | 90 (9.0) | ||||||
Association between three SNPs in 8q24 and risk of lung cancer.
| SNP | Genotype | Test set (548/556) | Validation set (453/507) | Pooled (1001/1063) | ||||||
| No. | OR (95% CI) |
| No. | OR (95% CI) |
| No. | OR (95% CI) |
| ||
| rs1447295 | CC | 406/407 | Reference | 323/381 | Reference | 729/788 | Reference | |||
| AC | 129/139 | 0.933 (0.708–1.231) | 0.625 | 116/118 | 1.166 (0.866–1.568) | 0.312 | 245/257 | 1.033 (0.844–1.264) | 0.756 | |
| AA | 13/10 | 1.336 (0.578–3.087) | 0.498 | 14/8 | 2.172 (0.896–5.268) | 0.086 | 27/18 | 1.678 (0.915–3.079) | 0.094 | |
|
| 0.782 | 0.079 | 0.167 | |||||||
| rs16901979 | CC | 263/285 | Reference | 209/248 | Reference | 472/533 | Reference | |||
| AC | 237/228 | 1.128 (0.880–1.444) | 0.342 | 208/215 | 1.152 (0.883–1.502) | 0.298 | 445/443 | 1.138 (0.950–1.364) | 0.162 | |
| AA | 48/43 | 1.215 (0.779–1.896) | 0.39 | 36/44 | 0.963 (0.596–1.554) | 0.876 | 84/87 | 1.091 (0.789–1.510) | 0.598 | |
|
| 0.339 | 0.655 | 0.321 | |||||||
| rs6983267 | TT | 135/173 | Reference | 115/164 | Reference | 250/337 | Reference | |||
| GT | 276/269 | 1.285 (0.967–1.708) | 0.084 | 214/231 | 1.335 (0.986–1.809) | 0.062 | 490/500 | 1.311 (1.066–1.613) | 0.010 | |
| GG | 136/114 | 1.532 (1.090–2.153) | 0.014 | 123/112 | 1.591 (1.118–2.264) | 0.010 | 259/226 | 1.555 (1.218–1.986) | 4.0×10−4 | |
|
| 0.013 | 0.009 | 3.4×10−4 | |||||||
cases/controls.
adjusted for age, sex and smoking status.
Genotype distribution of three SNPs by histology in patients and controls.
| SNP | Genotype | Adenocarcinoma | Squamous cell carcinoma | Others | ||||||
| No. | OR (95% CI) |
| No. | OR (95% CI) |
| No. | OR (95% CI) |
| ||
| rs1447295 | CC | 451/788 | Reference | 192/788 | Reference | 82/788 | Reference | |||
| AC | 173/257 | 1.243 (0.989–1.563) | 0.063 | 44/257 | 0.716 (0.496–1.035) | 0.076 | 28/257 | 1.048 (0.665–1.651) | 0.840 | |
| AA | 22/18 | 2.260 (1.174–4.353) | 0.015 | 2/18 | 0.555 (0.124–2.480) | 0.440 | 3/18 | 1.781 (0.502–6.311) | 0.371 | |
|
| 0.005 | 0.057 | 0.427 | |||||||
| rs16901979 | CC | 295/533 | Reference | 118/533 | Reference | 56/533 | Reference | |||
| AC | 286/443 | 1.189 (0.965–1.465) | 0.103 | 109/443 | 1.088 (0.805–1.469) | 0.584 | 49/443 | 1.053 (0.704–1.573) | 0.803 | |
| AA | 65/87 | 1.350 (0.946–1.926) | 0.098 | 11/87 | 0.546 (0.279–1.069) | 0.077 | 8/87 | 0.678 (0.297–1.543) | 0.354 | |
|
| 0.041 | 0.396 | 0.747 | |||||||
| rs6983267 | TT | 165/337 | Reference | 66/337 | Reference | 19/337 | Reference | |||
| GT | 328/500 | 1.327 (1.049–1.679) | 0.018 | 100/500 | 1.018 (0.718–1.445) | 0.919 | 58/500 | 1.986 (1.157–3.408) | 0.013 | |
| GG | 151/226 | 1.330 (1.003–1.763) | 0.048 | 72/226 | 1.775 (1.201–2.625) | 0.004 | 36/226 | 3.012 (1.675–5.417) | 2.3×10−4 | |
|
| 0.035 | 0.006 | 1.9×10−4 | |||||||
cases/controls.
adjusted for age, gender and smoking status.
Genotype distribution of three SNPs by smoking status in patients and controls.
| SNP | Genotype | Never | Current | Former | ||||||
| No. | OR (95% CI) |
| No. | OR (95% CI) |
| No. | OR (95% CI) |
| ||
| rs1447295 | CC | 275/407 | Reference | 295/278 | Reference | 121/61 | Reference | |||
| AC | 95/122 | 1.127 (0.820–1.548) | 0.461 | 104/82 | 1.173 (0.840–1.639) | 0.349 | 28/29 | 0.478 (0.254–0.898) | 0.022 | |
| AA | 10/10 | 1.588 (0.623–4.045) | 0.333 | 10/7 | 1.463 (0.543–3.942) | 0.451 | 3/0 | |||
|
| 0.270 | 0.249 | 0.022 | |||||||
| rs16901979 | CC | 175/283 | Reference | 197/181 | Reference | 79/41 | Reference | |||
| AC | 168/207 | 1.288 (0.968–1.715) | 0.083 | 184/154 | 1.122 (0.834–1.510) | 0.446 | 60/46 | 0.674 (0.380–1.193) | 0.175 | |
| AA | 37/49 | 1.049 (0.654–1.682) | 0.843 | 28/32 | 0.803 (0.464–1.390) | 0.433 | 13/3 | 2.650 (0.660–10.640) | 0.169 | |
|
| 0.302 | 0.937 | 0.991 | |||||||
| rs6983267 | TT | 95/170 | Reference | 100/118 | Reference | 42/27 | Reference | |||
| GT | 174/274 | 1.160 (0.841–1.600) | 0.366 | 203/167 | 1.446 (1.032–2.027) | 0.032 | 74/40 | 1.509 (0.782–2.912) | 0.220 | |
| GG | 114/95 | 2.366 (1.605–3.488) | 1.4×10−5 | 104/82 | 1.430 (0.962–2.126) | 0.077 | 36/23 | 1.180 (0.558–2.495) | 0.665 | |
|
| 2.8×10−5 | 0.063 | 0.498 | |||||||
cases/controls.
adjusted for age and gender.
AA+AC vs CC.
Figure 1Kaplan–Meier survival curves for lung cancer patients in the Zhejiang study population with different rs6983267 genotypes.
A: all lung cancer patients. B: patients with stage III–IV tumors.
Association between three SNPs on 8q24 and survival in patients with lung cancer.
| SNP | Genotype | Zhejiang population | Fujian population | ||||||
| No. of patients | No. of death (%) | HR (95% CI) |
| No. of patients | No. of death (%) | HR (95% CI) |
| ||
| rs1447295 | CC | 209 | 153 (72.9) | Reference | 255 | 169 (73.2) | Reference | ||
| AC | 70 | 52 (24.8) | 0.983 (0.712–1.358) | 0.918 | 79 | 53 (22.9) | 1.025 (0.751–1.399) | 0.877 | |
| AA | 6 | 5 (2.4) | 2.272 (0.916–5.634) | 0.077 | 15 | 9 (3.9) | 1.097 (0.548–2.193) | 0.794 | |
| Global | 0.201 | 0.958 | |||||||
| rs16901979 | CC | 139 | 99 (47.1) | Reference | 165 | 109 (47.2) | Reference | ||
| AC | 119 | 90 (42.9) | 1.079 (0.807–1.444) | 0.607 | 160 | 105 (45.5) | 0.969 (0.739–1.2720 | 0.823 | |
| AA | 27 | 21 (10.0) | 1.041 (0.635–1.705) | 0.874 | 24 | 17 (7.4) | 1.524 (0.907–2.561) | 0.111 | |
| Global | 0.876 | 0.224 | |||||||
| rs6983267 | TT | 75 | 49 (23.3) | Reference | 89 | 61 (26.4) | Reference | ||
| GT | 140 | 105 (50.0) | 1.411 (0.986–2.018) | 0.060 | 158 | 110 (47.6) | 1.081 (0.750–1.558) | 0.675 | |
| GG | 70 | 56 (26.7) | 1.646 (1.099–2.464) | 0.016 | 100 | 60 (26.0) | 1.218 (0.884–1.678) | 0.227 | |
| Global | 0.049 | 0.464 | |||||||
adjusted for age, sex, smoking status, tumor stage, histology and histological grade.